News
Hypofractionated radiotherapy: New normal for lung cancer?
Almost 20% of lung cancer patients in a U.K. study had their radiotherapy dose or fractionation schedule changed during the first wave of the...
News
Camrelizumab ‘another brick in the wall’ against squamous NSCLC
Adding camrelizumab to chemotherapy improved survival in patients with squamous non–small cell lung cancer.
News
Can benefits of SBRT outweigh risks in ultra-central lung tumors?
Stereotactic body radiotherapy for ultra-central lung tumors offers good disease control and survival but carries a risk of lung hemorrhage.
News
KRYSTAL-1: Clear activity of adagrasib in KRAS-mutated NSCLC
Phase 1/2 results with adagrasib confirm KRAS G12C as a druggable target in non–small cell lung cancer.
News
RA expert updates latest pathologic findings from Accelerating Medicines Partnership
Researchers have used single-cell analytic techniques to reveal pathologic RA synovial tissue differences in stromal and immune cells between...
News
No benefit seen with everolimus in early breast cancer
There were no improvements in survival when everolimus was added to hormone therapy.
News
OA risk-reduction program targets injured knees
The Stop Osteoarthritis program is currently testing the feasibility of a three-part intervention to help prevent posttraumatic knee OA.
News
Pandemic puts patients with psoriatic disease off seeking medical help
Both the physical and mental health of people with psoriasis and psoriatic arthritis has been affected by the ongoing COVID-19 pandemic.
News
Rheumatologic disease activity an important influencer of COVID-19 death risk
COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from...
News
Entinostat doesn’t overcome endocrine resistance in advanced breast cancer
Phase 3 results do not support use of entinostat in advanced breast cancer.
News
Study: Doctors underreport side effects of breast irradiation
A large study shows a mismatch between patient and physician reports of toxicity.
News
No edge for anastrozole over tamoxifen in DCIS
Breast cancer recurrence rates were similar at almost 12 years of follow-up.
News
Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients
PRIME-2 study results show no drop in overall survival from omitting postop radiotherapy in older women with HR+, low-risk, early-stage breast...
News
An all-oral option for advanced HR+, HER2– breast cancer?
Adding the oral taxane tesetaxel to capecitabine improved progression-free survival.